NeuroEyes announced on the 29th that its medical device 'NeuroEyes Anna' has received approval from the U.S. Food and Drug Administration (FDA). NeuroEyes Anna diagnoses dizziness using virtual reality (VR).
The number of dizziness patients is increasing in an ultra-aged society. NeuroEyes Anna diagnoses dizziness using a virtual reality device that has already been commercialized in the market. It has a lower expense compared to existing equipment and does not take up much space, allowing for testing in general examination rooms.
Patients can immerse themselves in testing for dizziness as if they are playing a game in virtual reality. Medical staff can receive diagnostic data. NeuroEyes Anna has been introduced to over 120 medical institutions in the country. NeuroEyes was established in 2021 as a subsidiary of Hallym University Technology Holding Company. Seo Gyuwon, the CEO of NeuroEyes, noted, 'We will commercialize a digital treatment for dizziness.'